Trial
NCT01677182
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Bipolar Disorder
Intervention
Ramelteon
Why stopped
Business Decision; Terminated due to futility, with no safety concerns (see below)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-16